

- 17. A method according to claim 11, wherein during the period lamivudine as the nucleoside analogue is administered in a dose from 50 to 150 mg per day.
- 18. A method according to claim 11, wherein during the period interferon-α is administered in a dose from 30 megaUnits to 15 megaUnits per week.
- 19. A kit of parts, comprising at least a first container and a second container, wherein the first container comprises a nucleoside analogue and the second container comprises interferon-α.
- 20. A kit of parts according to claim 19, wherein the nucleoside analogue is lamivudine, adefovir, or entecavir.--

Remarks

Claims 11-20 are pending in this application. Support for these claims appears in the specification and original claims 1-10.

If there is any fee due in connection with the filing of this Preliminary Amendment, please charge the fee to our Deposit Account No. 06-0916.

Respectfully submitted,

FINNEGAN, HENDERSON, FARABOW, GARRETT & DUNNER, L.L.P.

By:

Date: April 26, 2001

Steven J. Scott Reg. No. 43,911